VANGUARD PORTFOLIO MANAGEMENT LLC
Position in DNLI — Denali Therapeutics Inc.
CIK 2100121
MALVERN, PA
Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$166,589,906
+$49,082,834 QoQ
Shares Held
6,477,057
+5.8% QoQ
Ownership
4.05%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#6
of 290 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026VANGUARD PORTFOLIO MANAGEMENT LLC holds $28,900,028,271 across 295 Biotechnology names. DNLI ranks #40 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,878,987 | $2,423,539,212 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,175,313 | $1,979,934,668 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
6,538,390 | $1,968,251,541 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
8,294,855 | $1,553,460,444 | |
| 5 | INSM |
INSMED Inc
|
10,407,962 | $1,109,696,908 | |
| 6 | MRNA |
Moderna, Inc.
|
15,581,313 | $1,091,159,349 | |
| 7 | INCY |
Incyte Corp
|
7,791,091 | $883,198,075 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
21,641,339 | $765,886,987 |
All Filings in DNLI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $166,589,906 | 6,477,057 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $117,507,072 | 6,120,160 | Shares | Defined | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||